Targeting α₄β₁ integrin: from cyclic to linear ligands, effects of chemical modifications

Area of Science:

• Biochemistry
• Immunology
• Medicinal Chemistry

Background:

• Integrins are vital for immune cell adhesion, migration, and intracellular signaling.
• Dysregulation of integrin expression is linked to autoimmune diseases, inflammation, cancer, and infections.
• Targeting specific integrins, like α4β1, presents a promising therapeutic strategy.

Purpose of the Study:

• To synthesize and evaluate novel compounds for their affinity and potency against α4β1 integrin.
• To assess the selectivity of these compounds towards α5β1 and αMβ2 integrins.
• To explore the potential of these compounds as therapeutic agents for inflammatory diseases and cancer.

Main Methods:

• Synthesis of a novel series of chemical compounds.
• Evaluation of binding affinities (Ki) and potencies (IC50, EC50) towards α4β1, α5β1, and αMβ2 integrins.
• Cell adhesion assays and assessment of integrin-mediated intracellular signaling (ERK1/2, Akt phosphorylation).

Main Results:

• Compounds 3, 4, and 8 demonstrated high binding affinity (Ki < 10 nM) for α4β1 and acted as antagonists.
• Compound 4 showed dual activity: α4β1 antagonism and αMβ2 agonism.
• Compound 2 selectively activated α5β1, while compound 5 acted as an agonist for both α4β1 and α5β1, promoting signaling.
• Compound 8 was a highly potent agonist for αMβ2 (EC50 1.4 ± 0.2 nM).

Conclusions:

• The study identified novel integrin ligands with diverse functional profiles (agonists and antagonists).
• Compounds 3, 4, 5, and 8 show potential as lead compounds for therapeutic development.
• These ligands offer new insights for targeting integrins in inflammatory conditions and cancer therapy.